Review
Pharmacology & Pharmacy
Matt Shirley
Summary: The drug combination Netupitant/palonosetron is a fixed-dose combination indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in adults. It has shown high complete response rates in clinical trials and is well-tolerated in both oral and IV formulations. This drug combination provides a simple and convenient option for patients receiving highly or moderately emetogenic chemotherapy.
Article
Pharmacology & Pharmacy
Jouko Levijoki, Lasse Saloranta, Johanna Tuunainen, Janne Kaskinoro, Sari Pappinen, Sandra Nourry, Anne-Marie Betat, Anne Maurin, Maarit Pakarinen, Sari Hakkinen, Johanna Tervapuro, Hertta Pihlasvaara, Christophe Drieu La Rochelle, Heikki Joensuu
Summary: Ocular administration of palonosetron as eye drops can effectively prevent and treat nausea and vomiting. This method provides a quick and convenient way to deliver the medication when intravenous administration is not possible.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2023)
Article
Oncology
Jonas Nilsson, Vittoria Piovesana, Marco Turini, Claudio Lezzi, Jennifer Eriksson, Matti Aapro
Summary: This study assessed the cost-effectiveness of NEPA in the Spanish market and compared it to other available treatments. The results showed that NEPA is more effective and less costly compared to other treatments.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Hang Zhang, Qiang Zeng, Tian Dong, Xinchuan Chen, Pu Kuang, Jian Li, Qiuhui Wu, Ting Liu, Ting Niu, Zhigang Liu, Jie Ji
Summary: This study compared the efficacy of NEPA and 5HT(3)RA in preventing CINV among patients undergoing multiday conditioning chemotherapy prior to HSCT. The results showed that NEPA demonstrated superior efficacy compared to 5HT(3)RA during all phases, including rates of complete response, complete control, no vomiting, and no significant nausea.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Matti Aapro, Karin Jordan, Florian Scotte, Luigi Celio, Meinolf Karthaus, Eric Roeland
Summary: Chemotherapy-induced nausea and vomiting (CINV) is a common problem that affects patients' quality of life and the effectiveness of chemotherapy. NEPA, a fixed combination antiemetic, can improve adherence to guidelines and provide effective treatment for CINV.
CURRENT CANCER DRUG TARGETS
(2022)
Article
Oncology
Barbara Loteta, Annalisa Paviglianiti, Virginia Naso, Anna Ferreri, Tiziana Moscato, Giuseppe Console, Filippo Antonio Canale, Giuseppe Irrera, Marta Pugliese, Antonella Di Costanzo, Pasquale Fabio Provenzano, Viviana Loddo, Gaetana Porto, Giuseppa Cusumano, Letteria Russo, Nicola Meliambro, Valentina Romeo, Domenico Porcino, Salvatore Gallo, Tiziana Gangemi, Antonio Maria Rossetti, Massimo Martino
Summary: NEPA, without DEXA, proved to be a well-tolerated and effective antiemetic option for MM patients undergoing HDM followed by ASCT, with a 93% complete response rate within 120 hours.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, Luigi Cavanna, Olga Martelli, Simona Carnio, Elena Collova, Federica Bertolini, Fausto Petrelli, Alessandra Cassano, Rita Chiari, Francesca Zanelli, Salvatore Pisconti, Isabella Vittimberga, Antonietta Letizia, Andrea Misino, Angela Gernone, Erminio Bonizzoni, Sara Pilotto, Sabino De Placido, Emilio Bria
Summary: The study aimed to evaluate the noninferiority of a simplified regimen of NEPA plus single-dose DEX compared to the standard 4-day DEX treatment in high-dose cisplatin chemotherapy for preventing chemotherapy-induced nausea and vomiting. Results showed that the simplified regimen offered comparable antiemetic control over 5 days post-chemotherapy, with noninferiority met for both DEX-sparing regimens. This suggests that the simplified regimen may be a clinically relevant option for patients where caution with corticosteroid use is advised.
Article
Oncology
Maurice J. D. L. van der Vorst, Elisa C. Toffoli, Marlien Beusink, Myra E. van Linde, Theo van Voorthuizen, Saskia Brouwer, Annette A. van Zweeden, Suzan Vrijaldenhoven, Johan C. Berends, Johannes Berkhof, Henk M. W. Verheul
Summary: This study demonstrates that Dex-sparing regimens are noninferior to multiple-day Dex in controlling delayed nausea and vomiting in patients undergoing moderately emetogenic chemotherapy.
Article
Medicine, General & Internal
Yi Cheng, Zehua Wu, Lishuo Shi, Cailu Shen, Jianwei Zhang, Huabin Hu, Weiwei Li, Yue Cai, Xiaoyu Xie, Jiayu Ling, Qin Zheng, Yanhong Deng
Summary: This study evaluated the efficacy of aprepitant combined with palonosetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderate-emetogenic chemotherapy (MEC). The results showed that aprepitant was superior to dexamethasone in terms of achieving a complete response in preventing CINV, with fewer reported side effects in the aprepitant group.
Article
Oncology
Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, Luigi Cavanna, Olga Martelli, Simona Carnio, Elena Collova, Federica Bertolini, Fausto Petrelli, Alessandra Cassano, Rita Chiari, Francesca Zanelli, Salvatore Pisconti, Isabella Vittimberga, Antonietta Letizia, Andrea Misino, Angela Gernone, Erminio Bonizzoni, Sara Pilotto, Sabino De Placido, Emilio Bria
Summary: This study investigated the impact of reducing dexamethasone (DEX) on the daily lives of cisplatin-treated patients. The results showed that reducing the dose of DEX when administered with NEPA did not have any adverse effects on the daily functioning of the patients.
Article
Medicine, General & Internal
Eun Kyung Choi, Sang-Jin Park, Chanyang Park, Jung A. Lim
Summary: This study compared the prophylactic antiemetic effects of midazolam combined with palonosetron with palonosetron alone after laparoscopic cholecystectomy surgeries. The results showed that the combination therapy was more effective in preventing PONV and reducing the severity of nausea compared to palonosetron alone, with no significant difference in side effects between the two groups.
Article
Medicine, General & Internal
Christopher C. H. Yip, L. Li, Thomas K. H. Lau, Vicky T. C. Chan, Carol C. H. Kwok, Joyce J. S. Suen, Frankie K. F. Mo, Winnie Yeo
Summary: This retrospective analysis compared the efficacy of olanzapine-based and NEPA-based regimens in controlling chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving AC. The olanzapine group showed higher rates of no rescue therapy and no significant nausea during cycle 1 of AC. However, there were no differences in quality of life between the two groups. Multiple cycle assessment revealed higher rates of total control in the NEPA group in later cycles. These results do not support the superiority of either regimen for breast cancer patients receiving AC.
HONG KONG MEDICAL JOURNAL
(2023)
Article
Oncology
Nicola Di Renzo, Maurizio Musso, Rosanna Scime, Alessandra Cupri, Tommasina Perrone, Clara De Risi, Domenico Pastore, Attilio Guarini, Andrea Mengarelli, Fabio Benedetti, Patrizio Mazza, Saveria Capria, Patrizia Chiusolo, Luca Cupelli, Vincenzo Federico, Valentina Bozzoli, Anna Rita Messa, Rosella Matera, Davide Seripa, Paolo Codega, Erminio Bonizzoni, Giorgina Specchia
Summary: NEPA administered with a simplified every-other-day schedule shows to be very effective in preventing CINV in patients at high risk of CINV undergoing chemomobilization of stem cells prior to ASCT.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Pharmacology & Pharmacy
Yu-Chen Hsu, Ching-Yao Chen, Ka-Wai Tam, Chin-Yu Hsu
Summary: Palonosetron showed greater efficacy in preventing chemotherapy-induced nausea and vomiting compared to granisetron, especially in delayed phases, with no severe adverse effects observed.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Estevao Luiz Carvalho Braga, Nubia Vercosa, Ismar Lima Cavalcanti
Summary: The single use of fosaprepitant is equally effective as the use of palonosetron in preventing vomiting in the first 48 hours after laparoscopic cholecystectomy in women.
FRONTIERS IN PHARMACOLOGY
(2022)
